GOBO statistics

Tool stats & trends

Looking to identify usage trends or leading experts?


GOBO specifications


Unique identifier OMICS_12552
Alternative name Gene expression-based Outcome for Breast cancer Online
Interface Web user interface
Restrictions to use None
Computer skills Basic
Version 1.0.1
Stability Stable
Maintained Yes


  • person_outline Markus Ringnér

Publications for Gene expression-based Outcome for Breast cancer Online

GOBO citations


SPIN1, negatively regulated by miR 148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer

PMCID: 5944004
PMID: 29743122
DOI: 10.1186/s13046-018-0748-9

[…] ata indicate that the expression of the drug metabolizing enzymes CYP2C8, UGT2B4 and UGT2B17, and transporter ABCB4 was positively regulated by SPIN1 in breast cancer.Fig. 3Data from PPISURV [, ] and GOBO [] revealed that breast cancer patients with high expression of ABCB4 (P = 0.0242), CYP2C8 (P = 0.02028), UGT2B4 (P = 0.0181) or UGT2B17 (P = 0.00815) showed poorer survival than those with low e […]


Epigenetic alterations to Polycomb targets precede malignant transition in a mouse model of breast cancer

Sci Rep
PMCID: 5882905
PMID: 29615825
DOI: 10.1038/s41598-018-24005-x

[…] gnificantly reduced expression (FDR < 0.05) as a gene panel to test if they can predict metastasis risk in human patients. We applied the gene list to Gene Expression-Based Outcome for Breast Cancer (GOBO) and found there was a significant difference on distant metastasis-free survival (DMFS) between patients with high and low expression of those genes (Supplementary Fig. ). This suggests potentia […]


ESE 1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells

PMCID: 5642504
PMID: 29050229
DOI: 10.18632/oncotarget.18710

[…] e range of ESE-1 mRNA expression, starting from very low or negative log values to very high, and with only HER2+ breast tumors and cell lines segregating with very high mRNA expression of ESE-1 (–). GOBO analysis revealed that the high expression of ESE-1 in HER2+ cells has clinical significance (Figure ). Patients expressing high ESE-1 mRNA have a significantly poorer RFS than their ESE-1-negati […]


Comparative analysis of genes frequently regulated by drugs based on connectivity map transcriptome data

PLoS One
PMCID: 5456389
PMID: 28575118
DOI: 10.1371/journal.pone.0179037

[…] dy and drug discovery. For example, Shin et al developed GENT to compare expression status of genes between normal and tumor tissues profiled by Affymetrix U133A or U133plus2 microarray platforms []. GOBO is a database for breast cancer in which multiple analyses on transcriptome data, including survival analysis, comparative analysis and co-expression analysis could be performed []. What’s more, […]


TRPV4 plays a role in breast cancer cell migration via Ca2+ dependent activation of AKT and downregulation of E cadherin cell cortex protein

PMCID: 5523072
PMID: 28530703
DOI: 10.1038/oncsis.2017.39

[…] mics approach, our lab previously identified TRPV4 to play a role in breast cancer metastasis. Furthermore, meta-analysis of public databases through multifunctional online tools (http://co.bmc.lu.se/gobo,http://kmplot.com/analysis), TRPV4 expression in breast cancer patients was shown to correlate with a more aggressive phenotype, a poorer overall and distant metastasis-free survival (DMFS) in a […]


DCYTB is a predictor of outcome in breast cancer that functions via iron independent mechanisms

PMCID: 5341190
PMID: 28270217
DOI: 10.1186/s13058-017-0814-9

[…] ch DCYTB influences this complex pathway.Consistent with an inhibitory role of DCYTB on FAK activation, analysis of two combined cohorts that together total 1610 breast cancer patients as well as the GOBO cohort (n = 1379) revealed that high DCYTB expression was associated with longer distant metastasis-free survival and longer relapse-free survival (both local and distant) (Fig. , Additional file […]


Looking to check out a full list of citations?

GOBO institution(s)
Department of Oncology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden; CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
GOBO funding source(s)
The present study was supported by the Swedish Cancer Society, the Foundation for Strategic Research through the Lund Strategic Centre for Translational Cancer Research (CREATE Health), and the Swedish Research Council.

GOBO reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review GOBO